viewOptiBiotix Health PLC

OptiBiotix surges as SlimBiome granted CE mark and medical device status

The CE mark allows the product to be marketed within the EEA, as well as providing eligibility for shortened medical product registration in markets such as China and the UAE

Weight loss
SlimBiome is marketed as a weight management system

Shares in OptiBiotix Health plc (LON:OPTI) surged in early trading Tuesday after its SlimBiome weight loss product received a CE mark as well as medical device status.

The CE mark allows the product to be freely marketed within the European Economic Area (EEA), as well as providing eligibility for shortened medical product registration procedures in other markets such as China and the United Arab Emirates.

READ: OptiBiotix Health inks distribution deal covering Greece and Cyprus

CE-marked products may also make medicinal or medical claims supported by clinical studies, a factor that would extend the application of SlimBiome from food products to medical products.

The company added that the product will be manufactured in Europe and sold as SlimBiome Medical to pharmacies and major retailers.

Stephen O'Hara, chief executive of OptiBiotix, said the new mark and status for SlimBiome would open up access to consumer healthcare and pharmaceutical markets, adding that in combination with “a number of clinical studies showing SlimBiome's effectiveness, a large IP portfolio [and] two industry awards”, there were now “clear differentiators” from other weight loss products which he hoped would “contribute substantive revenues to OptiBiotix's growth”.

The development follows other European news last week when the firm clinched a three-year distribution contract in Greece and Cyprus for its LPLDL cholesterol and blood pressure product.

Shares were up 17.8% at 86p.

--Adds share price--

Quick facts: OptiBiotix Health PLC

Price: 69.3 GBX

Market: AIM
Market Cap: £59.21 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...



Full interview: European healthcare broker sets 97p price target for...

OptiBiotix Health PLC's (LON:OPTI) Stephen O'Hara speaks to Proactive London following a research note whcih has been published on the company by Goetz partners - which has set OPTI a price target of 97p. O'Hara says Goetz partners are a leading European Investment Bank and broking firm and...

on 11/9/19

2 min read